New cocktail of drugs aims to fight advanced stomach cancer
NCT ID NCT07315750
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a combination of three drugs (disitamab vedotin, trastuzumab, and tislelizumab) works better than standard chemotherapy plus trastuzumab with or without pembrolizumab for people with advanced HER2-high stomach or gastroesophageal junction cancer. The study will enroll 555 participants who have not had prior treatment for advanced disease. The main goal is to see if the new combo delays cancer progression or improves survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Disitamab vedotin, trastuzumab, tislelizumab, CAPOX chemotherapy, pembrolizumab
- What this could lead to
- If this works, it could offer a more effective first-line treatment option for people with advanced HER2-high stomach cancer, potentially extending life without progression.
- What could go wrong
- This is an early-stage phase 3 trial with 555 participants, so results are not yet known. The new combination may not be better than standard therapy and could have more side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, BJ-Beijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- New PET tracer could spot cancers that standard scans overlook
- New hope for advanced cancer patients as experimental drug enters human testing.
- Personalized blood test aims to track stomach and colon cancer spread
- New antibody drug aims to turn immune cells against cancer
- Tiny plastics, big danger? new study probes link to stomach cancer